McKinsey Exec On Pharma's Digital Shift, Deal-Making Expectations
McKinsey India's head of pharmaceutical and healthcare practice shares insights on pharma’s risk management efforts and accelerated deployment of digital technologies, including augmented reality headsets for shop floor operators amid the pandemic. He expects a broad surge in deal-making and says pharma is poised for a “full recovery” soon.
You may also be interested in...
Technologies like head-mounted tablets became critical for method transfers, virtual inspections and more. Cloud-based submissions could be next …
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
Scrip takes a look at the key trends that could play out in 2021 to shape the trajectory of Indian drug makers, including evolving dynamics in the US under a new president. Thorny India-China relations will add a layer of complexity, while firms may also want to look beyond the chief information officers as they ramp up digital engagement.